



=> d l1
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l8
 L8 HAS NO ANSWERS
 L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'REGISTRY' ENTERED AT 10:55:13 ON 28 DEC 2006)

DEL HIS
 L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 24 S L1
 L4 1 S IMIDAZOLE/CN
 L5 803817 S 16.195/RID
 L6 50 S L1 SAM SUB=L5
 L7 18955 S L1 FUL SUB=L5
 L8 STRUCTURE UPLOADED
 L9 QUE L8
 L10 37 S L8 SAM SUB=L7
 L11 745 S L8 FUL SUB=L7
 L12 742 S L11 AND CAPLUS/LC
 L13 3 S L11 NOT L12

FILE 'CAPLUS' ENTERED AT 11:03:58 ON 28 DEC 2006

L14 25 S L11

888
 12/28/06

SRNT


10/777,488

13 of 25

Page 1

L14 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:725467 CAPLUS <<LOGINID::20061228>>
DOCUMENT NUMBER: 133:296436
TITLE: Heterocyclylbiphenyl aP2 inhibitors
INVENTOR(S): Robl, Jeffrey A.; Sulsky, Richard B.; Magnin, David R.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 206 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059506	A1	20001012	WO 2000-US7417	20000320
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6548529	B1	20030415	US 2000-519079	20000306
CA 2366871	A1	20001012	CA 2000-2366871	20000320
BR 2000009563	A	20020115	BR 2000-9563	20000320
EP 1181014	A1	20020227	EP 2000-918177	20000320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102874	T2	20020321	TR 2001-2874	20000320
HU 200202251	A2	20021128	HU 2002-2251	20000320
JP 2002541106	T	20021203	JP 2000-609070	20000320
EE 200100504	A	20021216	EE 2001-504	20000320
NZ 513493	A	20040227	NZ 2000-513493	20000320
ZA 2001006856	A	20021120	ZA 2001-6856	20010820
LT 4921	B	20020625	LT 2001-92	20010925
BG 105968	A	20020531	BG 2001-105968	20011002
NO 2001004823	A	20011004	NO 2001-4823	20011004
LV 12782	B	20020620	LV 2001-155	20011102
US 2003199563	A1	20031023	US 2002-321137	20021217
US 6927227	B2	20050809		
PRIORITY APPLN. INFO.:			US 1999-127745P	P 19990405
			US 2000-519079	A3 20000306
			WO 2000-US7417	W 20000320
OTHER SOURCE(S):				
GI				
MARPAT 133:296436				



AB AP2 inhibiting biphenyls substituted in the 2-position by a substituted 5-membered heterocycle and in the 3'-position by a carboxyalkyl, carboxyalkenyl, carboxymethoxy, carboxymethylamino, or 5-tetrazolylmethyl group, were prepared. The compds. are useful for treating diabetes and related diseases, especially Type II diabetes (no data) and may be used in combination with another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin. Thus, 2-BrC₆H₄CO₂H was treated with benzoin and the resulting keto ester cyclized to give 2-(2-bromophenyl)-4,5-diphenyloxazole which was coupled with 3-OCHC₆H₄B(OH)₂ to give the biphenyl derivative I [R = CHO]. Reduction of the formyl group, chlorination,

and reaction with NaCN gave I [R = CH₂CN] which was cyclized with Me₃SnN₃ to give I [R = 5-tetrazolylmethyl].


IT 300657-24-3P 300657-25-4P 300657-26-5P
300657-27-6P 300657-28-7P 300657-29-8P
300657-30-1P 300657-31-2P 300657-32-3P
300657-33-4P 300657-34-5P 300657-35-6P
300657-94-7P 300657-95-8P 300657-97-0P
300657-98-1P 300657-99-2P 300658-01-9P
300658-02-0P 300658-03-1P 300658-04-2P
300658-05-3P 300658-06-4P 300658-17-7P
300658-18-8P 300658-20-2P 300658-21-3P
300658-22-4P 300658-24-6P 300658-25-7P
300658-26-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclylbiphenyl derivs. as aP2 inhibitors)


RN 300657-24-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxaldehyde, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 300657-25-4 CAPLUS

CN [1,1'-Biphenyl]-3-methanol, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)




RN 300657-26-5 CAPLUS

CN 1H-Imidazole, 2-[3'-(chloromethyl)[1,1'-biphenyl]-2-yl]-1-ethyl-4,5-diphenyl- (9CI) (CA INDEX NAME)




RN 300657-27-6 CAPLUS

CN [1,1'-Biphenyl]-3-acetonitrile, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)




RN 300657-28-7 CAPLUS

CN [1,1'-Biphenyl]-3-amine, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)- (9CI)
(CA INDEX NAME)




RN 300657-29-8 CAPLUS

CN Glycine, N-[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)][1,1'-biphenyl]-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300657-30-1 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 300657-31-2 CAPLUS

CN 1H-Imidazole, 1-ethyl-2-(3'-methoxy[1,1'-biphenyl]-2-yl)-4,5-diphenyl- (9CI) (CA INDEX NAME)




RN 300657-32-3 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 2'-((1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)- (9CI)
(CA INDEX NAME)



RN 300657-33-4 CAPLUS


CN Acetic acid, [[2'-((1-ethyl-4,5-diphenyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 300657-34-5 CAPLUS


CN 2-Propenoic acid, 3-[2'-((1-ethyl-4,5-diphenyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 300657-35-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanoic acid, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 300657-94-7 CAPLUS

CN Acetic acid, [[2'-(4,5-diphenyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300657-95-8 CAPLUS

CN Acetic acid, [[2'-[4,5-diphenyl-1-(2-propenyl)-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300657-97-0 CAPLUS

CN 1H-Imidazole, 1-methyl-4,5-diphenyl-2-[3'-(phenylmethoxy)[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




RN 300657-98-1 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 2'-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 300657-99-2 CAPLUS

CN Acetic acid, [[2'-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300658-01-9 CAPLUS

CN [1,1'-Biphenyl]-3-amine, 2'-(4,5-diphenyl-1-propyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 300658-02-0 CAPLUS

CN Glycine, N-[2'-(4,5-diphenyl-1-propyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300658-03-1 CAPLUS

CN [1,1'-Biphenyl]-3-amine, 2'-(4,5-diphenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 300658-04-2 CAPLUS

CN Glycine, N-[2'-(4,5-diphenyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300658-05-3 CAPLUS

CN [1,1'-Biphenyl]-3-amine, 2'-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 300658-06-4 CAPLUS

CN Glycine, N-[2'-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300658-17-7 CAPLUS

CN 1H-Imidazole-1-ethanol, 2-(3'-amino[1,1'-biphenyl]-2-yl)-4,5-diphenyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 300658-18-8 CAPLUS

CN Glycine, N-[2'-[1-[2-(acetyloxy)ethyl]-4,5-diphenyl-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300658-20-2 CAPLUS

CN [1,1'-Biphenyl]-3-amine, 2'-[1-(2-methylpropyl)-4,5-diphenyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 300658-21-3 CAPLUS

CN Glycine, N-[2'-[1-(2-methylpropyl)-4,5-diphenyl-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 300658-22-4 CAPLUS

CN Acetonitrile, [[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 300658-24-6 CAPLUS

CN 1H-Imidazole-1-acetic acid, 2-(3'-amino[1,1'-biphenyl]-2-yl)-4,5-diphenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 300658-25-7 CAPLUS

CN 1H-Imidazole-1-acetic acid, 2-[3'-[[2-(1,1-dimethylethoxy)-2-oxoethyl]amino][1,1'-biphenyl]-2-yl]-4,5-diphenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 300658-26-8 CAPLUS

CN Acetonitrile, [[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)][1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)




IT	<u>300656-35-3P</u>	<u>300656-36-4P</u>	<u>300656-37-5P</u>
	<u>300656-38-6P</u>	<u>300656-39-7P</u>	<u>300656-40-0P</u>
	<u>300656-41-1P</u>	<u>300656-64-8P</u>	<u>300656-65-9P</u>
	<u>300656-66-0P</u>	<u>300656-67-1P</u>	<u>300656-68-2P</u>
	<u>300656-69-3P</u>	<u>300656-75-1P</u>	<u>300656-76-2P</u>
	<u>300656-77-3P</u>	<u>300656-78-4P</u>	<u>300656-80-8P</u>
	<u>300656-81-9P</u>	<u>300656-84-2P</u>	<u>300656-85-3P</u>
	<u>300656-86-4P</u>	<u>300656-87-5P</u>	<u>300657-11-8P</u>
	<u>300657-12-9P</u>	<u>300657-13-0P</u>	

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclylbiphenyl derivs. as aP2 inhibitors)


RN 300656-35-3 CAPLUS

CN 1H-Tetrazole, 5-[[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 300656-36-4 CAPLUS

CN Glycine, N-[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 300656-37-5 CAPLUS

CN 1H-Tetrazole, 5-[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 300656-38-6 CAPLUS


CN Acetic acid, [[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)



RN 300656-39-7 CAPLUS


CN 2-Propenoic acid, 3-[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 300656-40-0 CAPLUS

CN [1,1'-Biphenyl]-3-acetic acid, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)




RN 300656-41-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanoic acid, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)




RN 300656-64-8 CAPLUS

CN Acetic acid, [[2'-(4,5-diphenyl-1H-imidazol-2-yl)][1,1'-biphenyl]-3-yl]oxy]-
(9CI) (CA INDEX NAME)




RN 300656-65-9 CAPLUS

CN Acetic acid, [[2'-[4,5-diphenyl-1-(2-propenyl)-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 300656-66-0 CAPLUS

CN Acetic acid, [[2'-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 300656-67-1 CAPLUS

CN Glycine, N-[2'-(4,5-diphenyl-1-propyl-1H-imidazol-2-yl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 300656-68-2 CAPLUS

CN Glycine, N-[2'-(4,5-diphenyl-1H-imidazol-2-yl)][1,1'-biphenyl]-3-yl]- (9CI)
(CA INDEX NAME)




RN 300656-69-3 CAPLUS

CN Glycine, N-[2'-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 300656-75-1 CAPLUS

CN Glycine, N-[2'-(1-(2-hydroxyethyl)-4,5-diphenyl-1H-imidazol-2-yl)][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 300656-76-2 CAPLUS

CN Acetic acid, [[2'-(4-phenyl-1H-imidazol-2-yl)][1,1'-biphenyl]-3-yl]oxy-
(9CI) (CA INDEX NAME)




RN 300656-77-3 CAPLUS

CN Glycine, N-[2'-[1-(2-methylpropyl)-4,5-diphenyl-1H-imidazol-2-yl)][1,1'-
biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 300656-78-4 CAPLUS

CN 1H-Tetrazole-5-methanamine, N-[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-
yl)][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 300656-80-8 CAPLUS

CN 1H-Imidazole-1-acetic acid, 2-[3'--[(carboxymethyl)amino] [1,1'-biphenyl]-2-yl]-4,5-diphenyl- (9CI) (CA INDEX NAME)




RN 300656-81-9 CAPLUS

CN 1H-Tetrazole, 5-[[[2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl) [1,1'-biphenyl]-3-yl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 300656-84-2 CAPLUS

CN Acetic acid, [[2'-[4,5-bis(4-fluorophenyl)-1H-imidazol-2-yl] [1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 300656-85-3 CAPLUS

CN Acetic acid, [[2'-[1-ethyl-4,5-bis(4-fluorophenyl)-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 300656-86-4 CAPLUS

CN Acetic acid, [[2'-[1-(methoxymethyl)-4,5-diphenyl-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 300656-87-5 CAPLUS

CN Acetic acid, [[2'-[1-(2-fluoroethyl)-4,5-diphenyl-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 300657-11-8 CAPLUS

CN Glycine, N-[2'-[1-(2-fluoroethyl)-4,5-diphenyl-1H-imidazol-2-yl][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 300657-12-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanoic acid, 2'-[1-(2-fluoroethyl)-4,5-diphenyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 300657-13-0 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-(1-ethyl-4,5-diphenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:610391 CAPLUS <<LOGINID::20061228>>
DOCUMENT NUMBER: 105:210391
TITLE: Syntheses of photochromic substituted bislophines
AUTHOR(S): Yasuda, Goro; Inoue, Sinichi; Hori, Takuya
CORPORATE SOURCE: Aichi Inst. Technol., Japan
SOURCE: Aichi Kogyo Daigaku Kenkyu Hokoku, B: Senmon Kankei
Ronbunshu (1985), 20, 47-9
CODEN: AKDBDP; ISSN: 0387-0812
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



AB Ferricyanide oxidation products of I (R = H, Me, MeO, Cl) were photochromic.
IT 16408-45-0D, oxidized 105384-25-6D, oxidized
105384-26-7D, oxidized 105384-27-8D, oxidized
RL: USES (Uses),
(photochromic)
RN 16408-45-0 CAPLUS
CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-diphenyl]- (9CI) (CA
INDEX NAME)




RN 105384-25-6 CAPLUS
CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-bis(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 105384-26-7 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-bis(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 105384-27-8 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-bis(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




IT 16408-45-0P 105384-25-6P 105384-26-7P
105384-27-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and oxidation of)


RN 16408-45-0 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-diphenyl]- (9CI) (CA


INDEX NAME)



RN 105384-25-6 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-bis(4-methylphenyl)-
(9CI) (CA INDEX NAME)

RN 105384-26-7 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-bis(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)

RN 105384-27-8 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-bis(4-chlorophenyl)-
(9CI) (CA INDEX NAME)

L14 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1972:468079 CAPLUS <<LOGINID::20061228>>

DOCUMENT NUMBER: 77:68079

TITLE: Electronic structure and conformation of
aryl-substituted ω,ω' -bis(imidazol-2-yl)-p-
oligophenylsAUTHOR(S): Schneiders, Peter; Baumgaertel, Helmut; Heinze,
JuergenCORPORATE SOURCE: Inst. Phys. Chem., Univ. Freiburg, Freiburg, Fed. Rep.
Ger.SOURCE: Berichte der Bunsen-Gesellschaft (1972), 76(6), 556-69
CODEN: BBPCAX; ISSN: 0940-483X

DOCUMENT TYPE: Journal

LANGUAGE: German


AB The electronic excitation and polarization spectra of ω,ω' -bis(4,5-diphenylimidazol-2-yl)-p-oligophenyls and higher substituted derivs. were measured. The spectra were interpreted with the aid of SCF configuration interaction-calculns. in the Pariser-Parr-Pople approximation. The most intense electronic transitions are related to the A, H, B and C bands of p-oligophenyls. The longest wave transition of all compds. is polarized parallel to the long mol. axis. The conformations of the mols. in solution are discussed. With an increasing degree of substitution the outer substituents are more twisted against the plane of the heterocyclic system. This effect will be realized as well in the spectroscopical data as in the quantum mech. calculns. The intense fluorescence emission of the mols. was investigated. In it discussed in terms of structure. The phosphorescence emission observed at -190° is of $\pi-\pi^*$ -type. It is polarized in the plane of the mol. as far as measurable.

IT 16408-45-0 26261-14-3 26261-15-4
26261-20-1 26261-21-2 37165-76-7

RL: PRP (Properties)


(conformation and electronic structure of)

RN 16408-45-0 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[4,5-diphenyl- (9CI) (CA
INDEX NAME)


RN 26261-14-3 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[1,4,5-triphenyl- (9CI)
(CA INDEX NAME)




RN 26261-15-4 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1':4',1''-terphenyl]-4,4''-diylbis[1,4,5-triphenyl-
(9CI) (CA INDEX NAME)



RN 26261-20-1 CAPLUS

CN 1H-Imidazolium, 2,2'-[1,1'-biphenyl]-4,4''-diylbis[1,3,4,5-tetraphenyl-,
dichloride (9CI) (CA INDEX NAME)




●2 Cl⁻

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 26261-21-2 CAPLUS

CN 1H-Imidazolium, 2,2'-[1,1':4',1''-terphenyl]-4,4''-diylbis[1,3,4,5-
tetraphenyl-, dichloride (9CI) (CA INDEX NAME)



● 2 Cl⁻

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 37165-76-7 CAPLUS

CN 1H-Imidazole, 2,2'-[1,1':4',1''-terphenyl]-4,4''-diylbis[4,5-diphenyl-
(9CI) (CA INDEX NAME)

